A clinical trial of verapamil in amyotrophic lateral sclerosis

Muscle and Nerve

Volumn 19, Issue 4, 1996, Pages 511-515

  Miller, R G ^a,d   Smith, S A ^b   Murphy, J R ^c   Brinkmann, James R ^c   Graves, Joretta ^b   Mendoza, Michelle ^a   Sands, M L ^c   Ringel, S P ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

ALS; calcium channel blockers; clinical trial; neuromuscular disease; verapamil

Indexed keywords

VERAPAMIL;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MUSCLE STRENGTH; NEUROMUSCULAR DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

AMYOTROPHIC LATERAL SCLEROSIS; ANALYSIS OF VARIANCE; ARM; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; LEG; LUNG; MALE; MIDDLE AGED; VERAPAMIL;

EID: 0030006282     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/mus.880190405     Document Type: Article

References (23)

1. Alexianu ME, Ho BK, Mohamed AH, et al.: The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol 1994;36: 846-858
2. Andres PL, Thibodeau LM, Finison LJ, et al.: Quantitative assessment of neuromuscular deficit in ALS. Neurol Clin 1987;5:125-141.
3. Appel SH: Excitotoxic neuronal death in amyotrophic lateral sclerosis. Trends Neurosci 1993;16:3-4.
4. Beal MF: Mechanisms of excitotoxicity in neurologic diseases FasebJ 1992;6:3338-3344.
5. Brooks BR: El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial Clinical limits of amyotrophic lateral sclerosis workshop contributors. J Neurol Sci 1994;124:96-107.
6. Choi DW: Ionic dependence of glutamate neurotoxicity in cortical cell culture. J Neurol Sci 1987;7:369-379.
7. Choi DW: Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-634.
8. Cohen J: Statistical Power Analysis for the Behavioral Sciences Hillsdale, NJ, Lawrence Erlbaum Associates, 1988.
9. Corse AM, Rothstein JD: Organotypic spinal cord cultures and a model of chronic-glutamate mediated motor neuron degeneration, in Membrane Linked Disease; CNS Trauma: Laboratory Techniques and Recent Advancement Vol. 4 (Ohnishi, S.T. eds) CRC Press, in press.
10. Greenberg DA; Calcium channels and neuromuscular disease. Ann Neurol 1994;35:131-132.
11. Hellman S, Hellman DS: Of mice but not men: problems of the randomized clinical trials. N Engl J Med 1991;324: 1585-1589.
12. Lipton SA, Rosenberg PA: Mechanisms of disease: excitatory amino acids as a final common pathway for neurological disorders. N Engl J Med 1994;330.613-622.
13. 2+ currents in a motoneuron cell line. Ann Neurol 1995;37:102-109.
14. Olney JW, Sharpe LG: Brain lesions in an infant rhesus monkey treated with monosodium glutamate. Science 1969; 166: 386-388.
15. Palmer A, Fletcher A, et al.: A comparison of verapamil and infedipine on quality of life. Br J Clin Pharmacol 1990; 30:365-370.
16. Passamani E: Clinical trials. Are they ethical? N Engl J Med 1991;324:1589-1591.
17. Plaitakis A, Constantakakis E, Smith J: The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in ALS. Ann Neurol 1988;22:446-449.
18. Plaitakis A, Caroscio JT: Abnormal glutamate metabolism in ALS. Ann Neurol 1985;18:165.
19. Plaitakis A, Caroscio JT: Abnormal glutamate metabolism in ALS. Ann Neurol 1987;22:575-579.
20. Pradas J, Finison L, Andres PL, et al.: The natural history of amyotrophic lateral sclerosis and the use of natural history controls in therapeutic trials. Neurology 1993;43:751-755.
21. Ringel SP, Murphy JR, Alderson MK, et al.: The natural history of amyotrophic lateral sclerosis. Neurology 1993;43: 1316-1322.
22. Rothman SM, Olney JW: Excitatoxicity and the NMDA receptor trends. Trends Neurosci 1987;10:299-302.
23. Rothstein JD, Margin LJ, Kuncl RW: Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992;326:1464-1468.